GlassScriptPhysician profile
Sydur Rahman
NPI 1750771085
$3,109.25
in general payments reported to CMS, 2019-2025
13 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $403 · 2023: $222 · 2024: $320 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $836.96 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $635.65 | 2021-2025 | Caplyta |
| Abbvie INC. | $460.83 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $218.17 | 2024-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $209.03 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $192.91 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $163.41 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $137.66 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $98.35 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $89.81 | 2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $33.20 | 2025 | Cobenfy |
| Biogen, INC. | $17.37 | 2022 | |
| Horizon Therapeutics Plc | $15.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydur Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.